ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Insights into the spatial epidemiology of hepatitis C infection: systematic synthesis of area-level determinants and spatiotemporal analyses.BMC public health · 2025Pooled it
- Prevalence of Hepatitis C Virus Antibody Testing Across Geography, Time, and Social Vulnerability Among Adults in Florida, 2015-2021.Public health reports (Washington, D.C. : 1974) · 2026Article
- Viral Hepatitis Surveillance in the United States: Then, Now, and Looking Forward.Public health reports (Washington, D.C. : 1974) · 2025Article
- Prevalence of HIV, HBV, and HCV in United States blood donations, 2015-2023: The transfusion-transmissible infections monitoring system (TTIMS).Transfusion · 2025Article
- Hepatitis C Surveillance in the United States: Past, Present, and Future.Public health reports (Washington, D.C. : 1974) · 2025Review
- Hepatitis C Prevalence on the Rise but Screening at Safety Net Institutions Lagging behind.International journal of hepatology · 2023Article
- Exploring how hospitalization can alter hepatitis c virus treatment prioritization and trajectories in people who use drugs: A qualitative analysis.Substance abuse · 2022Article
- A Qualitative Study of Implementing Universal Hepatitis C Screening Among Adults at an Urban Community-Based Health Provider in Delaware.Delaware journal of public health · 2021Article
- Article
- Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Impact and costs of a hepatitis C virus screening programme for adults hospitalised at an academic medical centre.BMJ open quality · 2021Article
- The Geography of Opioid Use Disorder: A Data Triangulation Approach.Infectious disease clinics of North America · 2020Review
- Hepatitis C Coinfection and Mortality in People Living with HIV in Middle Tennessee.AIDS research and human retroviruses · 2020Observational
- Risk ofCancer prevention research (Philadelphia, Pa.) · 2019Article
- Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison.American journal of epidemiology · 2019Article
- Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance.Epidemics · 2019Article
- Delaware and Hepatitis C:: Is it time for universal screening?Delaware journal of public health · 2019Article
- The Epidemiology of Hepatocellular Carcinoma in the USA.Current gastroenterology reports · 2019Review
- Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention.Seminars in dialysis · 2019Review
- Short-term budget affordability of hepatitis C treatments for state Medicaid programs.BMC health services research · 2019Article
Corrections and comments
- Erratum issuedErratum.2017
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND.: Hepatitis C virus (HCV) infection is the most common chronic blood-borne infection in the United States and a leading cause of morbidity and mortality. Previous analyses of the US National Health and Nutrition Examination Survey (NHANES) indicated approximately 3.6 million noninstitutionalized persons with antibody to HCV (anti-HCV). However, state-level prevalence remains less understood and cannot be estimated reliably from NHANES alone. METHODS.: We used 3 publicly available government data sources to estimate anti-HCV prevalence in each US state among noninstitutionalized persons aged ≥18 years. A small-area estimation model combined indirect standardization of NHANES-based prevalence with logistic regression modeling of mortality data, listing acute or chronic HCV infection as a cause of death, from the National Vital Statistics System during 1999-2012. Model results were combined with US Census population sizes to estimate total number and prevalence of persons with antibody to HCV in 2010. RESULTS.: National anti-HCV prevalence was 1.67% (95% confidence interval [CI], 1.53-1.90), or 3 911 800 (95% CI, 3 589 400- 4 447 500) adults in 2010. State-specific prevalence ranged from 0.71% (Illinois) to 3.34% (Oklahoma). The West census region had the highest region-specific prevalence (2.14% [95% CI, 1.96-2.48]); 10 of 13 states had rates above the national average. The South had the highest number of persons with anti-HCV (n = 1561600 [95% CI, 1 427 700-1 768 900]). The Midwest had the lowest region-specific prevalence (1.14% [95% CI, 1.04%-1.30%]). CONCLUSIONS.: States in the US West and South have been most impacted by hepatitis C. Estimates of HCV infection burden are essential to guide policy and programs to optimally prevent, detect, and cure infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.